Asha Therapeutics

Asha Therapeutics is a life sciences company at the forefront of a new era in precision drug design, leveraging its proprietary PRISM™ technology to design compounds from scratch, creating disease-modifying and therapeutic treatments for neurological and infectious diseases with significant unmet medical needs. Asha's lead therapeutic programs, ASHA-624 and ASHA-091, target amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer’s disease, and are expected to enter clinical trials by late 2024 as disease-modifying therapies.